The ARASENS trial looked at the role of darolutamide in the treatment of patients with a type of prostate cancer called metastatic, hormone-sensitive prostate cancer. This plain language summary of publication, published in Future Oncology, provides an overview of this trial written in non-technical language. The summary includes commentary from patients and a caregiver and can help a wider audience, including patient advocates and healthcare professionals, understand the findings from this trial.
Learn more about the ARASENS trial originally published in the New England Journal of Medicine in this animated video that provides an overview of the plain language summary of publication.
Watch the video below or read the fully plain language summary here.